ANDA 209571, held by Xiromed. Darifenacin Hydrobromide.
As of Nov 16, 2026, ANDA 209571 (Darifenacin Hydrobromide), held by Xiromed, was first approved by FDA on Oct 22, 2019, with 0 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Oct 22, 2019 | Original application | Approved | None posted |
| Darifenacin HydrobromideEQ 15MG BASE · tablet, extended release;oral | Darifenacin Hydrobromide | Discontinued |
| Darifenacin HydrobromideEQ 7.5MG BASE · tablet, extended release;oral | Darifenacin Hydrobromide | Discontinued |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters